Your Partner in Neuroscience Drug Discovery

Your Partner in Neuroscience Drug Discovery

Exciting News! AxoSim Extends Leadership in Human Organoids for Neurological Drug Discovery
with Acquisition of StemoniX microBrain™ Technology! – Learn More!

AXOSIM PARTNERS WITH PRECLINICAL SCIENTISTS TO SOLVE ADVANCED PROBLEMS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESSES

Selection of drug candidates is a difficult and imperfect process requiring predictive modeling. Too often, animal and other preclinical models are not predictive in humans. Without this knowledge, selection of the wrong candidate can result in losses of money, time, and resources. We aim to help navigate this path by providing rodent and human predictive in vitro modeling.

Our industry leading biomimetic platforms enable us to work with our clients and partners to apply predictive data assisting in identification of better drug candidates, earlier, and more accurately and efficiently.

.

1) Drug Discovery: Shortening the time to lead candidate selection with human targets in phenotypic assays.
2) Preclinical: Broadening the preclinical funnel while shortening the time to clinical candidate selection.
3) Clinical: Accelerating IND filing with improved translation a success.

NerveSim®

How it Works

AxoSim's NerveSim® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.

BrainSim®

How it Works

BrainSim® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.

microBrain™

How it Works

The microBrain™ technology provides a physiologically-relevant human iPSC-derived screening platform for CNS drug discovery and toxicity testing.

News & Publications

Our Partners & Funders

At AxoSim, we frequently like to remind ourselves of our mission- empowering advancements in human neuroscience. We take a minute- away from the lab bench, protocols, schedules, budgets, and pipettes- and remember, that at the end of all the research, is people. Human beings that we know and love that are fighting daily battles with neurological diseases.

Megan Morris, MSE